Rybrevant

(amivantamab) Janssen

Composition:

• One mL of concentrate for solution for infusion contains 50 mg amivantamab. 
• One 7 mL vial contains 350 mg of amivantamab. 

Indications:

Rybrevant as monotherapy is indicated for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.